Insider Selling: Liquidia Co. (NASDAQ:LQDA) Insider Sells $31,785.00 in Stock

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 2,445 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total value of $31,785.00. Following the completion of the sale, the insider now owns 267,943 shares of the company’s stock, valued at $3,483,259. The trade was a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Rajeev Saggar also recently made the following trade(s):

• On Tuesday, January 14th, Rajeev Saggar sold 6,249 shares of Liquidia stock. The shares were sold at an average price of $11.78, for a total value of $73,613.22.

Liquidia Trading Down 0.3 %

Shares of NASDAQ LQDA opened at $14.36 on Friday. The firm’s 50-day moving average price is $11.65 and its 200-day moving average price is $11.09. The firm has a market capitalization of $1.22 billion, a P/E ratio of -8.81 and a beta of 0.23. Liquidia Co. has a 1-year low of $8.26 and a 1-year high of $16.99.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research note on Thursday, January 9th. Lifesci Capital began coverage on shares of Liquidia in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price target on the stock. Wells Fargo & Company began coverage on shares of Liquidia in a research report on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective for the company. Scotiabank initiated coverage on shares of Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Liquidia in a report on Thursday, November 14th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Liquidia has an average rating of “Buy” and an average target price of $25.38.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in LQDA. Profund Advisors LLC raised its position in shares of Liquidia by 31.6% during the second quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock worth $173,000 after purchasing an additional 3,466 shares during the period. Marshall Wace LLP acquired a new position in Liquidia during the second quarter worth $545,000. Squarepoint Ops LLC raised its holdings in Liquidia by 53.4% during the second quarter. Squarepoint Ops LLC now owns 82,272 shares of the company’s stock worth $987,000 after buying an additional 28,638 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Liquidia by 25.2% in the second quarter. The Manufacturers Life Insurance Company now owns 22,706 shares of the company’s stock valued at $272,000 after buying an additional 4,572 shares in the last quarter. Finally, Bluefin Capital Management LLC acquired a new position in shares of Liquidia during the second quarter valued at about $277,000. Institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).